drugset / Trial / NCT02514824
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Phase 1/2
Completed
9 enrolled
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma. \- The name of the study intervention involved in this study is: MLN0128.
Timeline
- Start
- 2015-10
- Primary completion
- 2017-04
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sapanisertib | Small molecule | 3 mg | Oral |
| Subject | Sapanisertib | Small molecule | 4 mg | Oral |
| Subject | Sapanisertib | Small molecule | 5 mg | Oral |